Novartis reported Phase III non‑inferiority results for GanLum (ganaplacide + lumefantrine), meeting WHO efficacy thresholds and showing high cure rates across study arms in sub‑Saharan Africa. The readout positions GanLum as a potential next‑generation antimalarial with efficacy against resistant strains and transmission‑blocking activity, and Novartis said it will seek regulatory approvals promptly. Success would introduce the first novel antimalarial in over two decades and help address rising artemisinin resistance.